Cargando…

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, van den Bosch, Filip, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, de Vlam, Kurt, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754738/
https://www.ncbi.nlm.nih.gov/pubmed/28684559
http://dx.doi.org/10.1136/annrheumdis-2017-211734
_version_ 1783290481588830208
author Smolen, Josef S
Schöls, Monika
Braun, Jürgen
Dougados, Maxime
FitzGerald, Oliver
Gladman, Dafna D
Kavanaugh, Arthur
Landewé, Robert
Mease, Philip
Sieper, Joachim
Stamm, Tanja
de Wit, Maarten
Aletaha, Daniel
Baraliakos, Xenofon
Betteridge, Neil
van den Bosch, Filip
Coates, Laura C
Emery, Paul
Gensler, Lianne S
Gossec, Laure
Helliwell, Philip
Jongkees, Merryn
Kvien, Tore K
Inman, Robert D
McInnes, Iain B
Maccarone, Mara
Machado, Pedro M
Molto, Anna
Ogdie, Alexis
Poddubnyy, Denis
Ritchlin, Christopher
Rudwaleit, Martin
Tanew, Adrian
Thio, Bing
Veale, Douglas
de Vlam, Kurt
van der Heijde, Désirée
author_facet Smolen, Josef S
Schöls, Monika
Braun, Jürgen
Dougados, Maxime
FitzGerald, Oliver
Gladman, Dafna D
Kavanaugh, Arthur
Landewé, Robert
Mease, Philip
Sieper, Joachim
Stamm, Tanja
de Wit, Maarten
Aletaha, Daniel
Baraliakos, Xenofon
Betteridge, Neil
van den Bosch, Filip
Coates, Laura C
Emery, Paul
Gensler, Lianne S
Gossec, Laure
Helliwell, Philip
Jongkees, Merryn
Kvien, Tore K
Inman, Robert D
McInnes, Iain B
Maccarone, Mara
Machado, Pedro M
Molto, Anna
Ogdie, Alexis
Poddubnyy, Denis
Ritchlin, Christopher
Rudwaleit, Martin
Tanew, Adrian
Thio, Bing
Veale, Douglas
de Vlam, Kurt
van der Heijde, Désirée
author_sort Smolen, Josef S
collection PubMed
description Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.
format Online
Article
Text
id pubmed-5754738
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57547382018-02-12 Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force Smolen, Josef S Schöls, Monika Braun, Jürgen Dougados, Maxime FitzGerald, Oliver Gladman, Dafna D Kavanaugh, Arthur Landewé, Robert Mease, Philip Sieper, Joachim Stamm, Tanja de Wit, Maarten Aletaha, Daniel Baraliakos, Xenofon Betteridge, Neil van den Bosch, Filip Coates, Laura C Emery, Paul Gensler, Lianne S Gossec, Laure Helliwell, Philip Jongkees, Merryn Kvien, Tore K Inman, Robert D McInnes, Iain B Maccarone, Mara Machado, Pedro M Molto, Anna Ogdie, Alexis Poddubnyy, Denis Ritchlin, Christopher Rudwaleit, Martin Tanew, Adrian Thio, Bing Veale, Douglas de Vlam, Kurt van der Heijde, Désirée Ann Rheum Dis Recommendation Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field. BMJ Publishing Group 2018-01 2017-07-06 /pmc/articles/PMC5754738/ /pubmed/28684559 http://dx.doi.org/10.1136/annrheumdis-2017-211734 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Recommendation
Smolen, Josef S
Schöls, Monika
Braun, Jürgen
Dougados, Maxime
FitzGerald, Oliver
Gladman, Dafna D
Kavanaugh, Arthur
Landewé, Robert
Mease, Philip
Sieper, Joachim
Stamm, Tanja
de Wit, Maarten
Aletaha, Daniel
Baraliakos, Xenofon
Betteridge, Neil
van den Bosch, Filip
Coates, Laura C
Emery, Paul
Gensler, Lianne S
Gossec, Laure
Helliwell, Philip
Jongkees, Merryn
Kvien, Tore K
Inman, Robert D
McInnes, Iain B
Maccarone, Mara
Machado, Pedro M
Molto, Anna
Ogdie, Alexis
Poddubnyy, Denis
Ritchlin, Christopher
Rudwaleit, Martin
Tanew, Adrian
Thio, Bing
Veale, Douglas
de Vlam, Kurt
van der Heijde, Désirée
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title_full Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title_fullStr Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title_full_unstemmed Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title_short Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
title_sort treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
topic Recommendation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754738/
https://www.ncbi.nlm.nih.gov/pubmed/28684559
http://dx.doi.org/10.1136/annrheumdis-2017-211734
work_keys_str_mv AT smolenjosefs treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT scholsmonika treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT braunjurgen treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT dougadosmaxime treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT fitzgeraldoliver treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT gladmandafnad treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT kavanaugharthur treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT landewerobert treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT measephilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT sieperjoachim treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT stammtanja treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT dewitmaarten treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT aletahadaniel treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT baraliakosxenofon treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT betteridgeneil treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT vandenboschfilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT coateslaurac treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT emerypaul treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT genslerliannes treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT gosseclaure treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT helliwellphilip treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT jongkeesmerryn treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT kvientorek treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT inmanrobertd treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT mcinnesiainb treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT maccaronemara treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT machadopedrom treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT moltoanna treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT ogdiealexis treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT poddubnyydenis treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT ritchlinchristopher treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT rudwaleitmartin treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT tanewadrian treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT thiobing treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT vealedouglas treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT devlamkurt treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce
AT vanderheijdedesiree treatingaxialspondyloarthritisandperipheralspondyloarthritisespeciallypsoriaticarthritistotarget2017updateofrecommendationsbyaninternationaltaskforce